Kluge, RegineWittig, TimGeorgi, Thomas WKurch, LarsSabri, OsamaWallace, W HamishKlekawka, TomaszFernández-Teijeiro, AnaCeppi, FrancescoKarlén, JonasPears, JaneCepelová, MichaelaFosså, AlexanderBeishuizen, AukeHjalgrim, Lisa LyngsieKörholz, DieterMauz-Körholz, ChristineHasenclever, Dirk2023-02-092023-02-092020-08-06http://hdl.handle.net/10668/16064In first-line treatment of Hodgkin lymphoma (HL), Deauville scores 1-3 define complete metabolic remission. Interim 18F-FDG PET is also used for relapse-treatment adaptation; however, PET response criteria are not validated for relapse treatment. Methods: We performed a pairwise comparative analysis of early response to first- and second-line treatments in 127 patients with classic HL who experienced relapse. The patients participated in the prospective, multicenter EuroNet-PHL-C1 study. Residual uptake was measured retrospectively using the qPET method, a validated semiautomatic quantitative extension of the Deauville score. Empiric cumulative distribution functions of the qPET values were used to systematically analyze the response to first- and second-line treatments. Results: Individual patients responded variably to first- and second-line treatments. However, the empiric cumulative distribution functions of the qPET values from all patients were nearly superimposable. Conclusion: The findings support that first- and second-line treatments in HL do not require different response criteria.enHodgkin lymphomaPET response criteriarelapseAdolescentChildDisease ProgressionFemaleHodgkin DiseaseHumansMalePositron-Emission TomographyRecurrenceTreatment Outcomeresearch article32764122open access10.2967/jnumed.120.2479241535-5667https://jnm.snmjournals.org/content/jnumed/62/3/338.full.pdf